Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma

Autor: Johnson, TG, Schelch, K, Cheng, YY, Williams, M, Sarun, KH, Kirschner, MB, Kao, S, Linton, A, Klebe, S, McCaughan, BC, Lin, RCY, Pirker, C, Berger, W, Lasham, A, van Zandwijk, N, Reid, G

© 2017 International Association for the Study of Lung Cancer Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignancy linked to asbestos exposure. On a genomic level, MPM is characterized by frequent chromosomal deletions of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d181f0418cc07b9d1444fe0a4eb09213
https://doi.org/10.5167/uzh-165114

3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies.

Autor: Shi H; Asbestos Diseases Research Institute, Concord, Sydney, NSW, Australia., Rath EM; Giannoulatou Laboratory, Victor Chang Cardiac Research Institute, Sydney, NSW, Australia., Lin RCY; Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Sydney, NSW, Australia.; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.; School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia., Sarun KH; Asbestos Diseases Research Institute, Concord, Sydney, NSW, Australia., Clarke CJ; Sydney Cardiothoracic Surgeons, Royal Prince Alfred Hospital (RPA) Medical Centre, Sydney, NSW, Australia., McCaughan BC; School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.; Sydney Cardiothoracic Surgeons, Royal Prince Alfred Hospital (RPA) Medical Centre, Sydney, NSW, Australia., Ke H; Asbestos Diseases Research Institute, Concord, Sydney, NSW, Australia.; Concord Repatriation General Hospital, Sydney, NSW, Australia., Linton A; Asbestos Diseases Research Institute, Concord, Sydney, NSW, Australia.; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.; Concord Repatriation General Hospital, Sydney, NSW, Australia., Lee K; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.; Concord Repatriation General Hospital, Sydney, NSW, Australia., Klebe S; Asbestos Diseases Research Institute, Concord, Sydney, NSW, Australia.; Pathology, Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia., Maitz J; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.; Concord Repatriation General Hospital, Sydney, NSW, Australia.; The ANAZC Research Institute, Sydney, NSW, Australia., Song K; State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, China., Wang Y; The ANAZC Research Institute, Sydney, NSW, Australia.; Jiangsu Provincial Engineering Research Centre of Traditional Chinese Medicine (TCM) External Medication Development and Application, Nanjing University of Chinese Medicine, Nanjing, China., Kao S; Asbestos Diseases Research Institute, Concord, Sydney, NSW, Australia.; Sydney Medical School, University of Sydney, Sydney, NSW, Australia., Cheng YY; Institute for Biomedical Materials & Devices, Faculty of Science, The University of Technology Sydney, NSW, Australia.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Aug 26; Vol. 12, pp. 973576. Date of Electronic Publication: 2022 Aug 26 (Print Publication: 2022).

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.

Autor: Williams M; Asbestos Diseases Research Institute, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia., Cheng YY; Asbestos Diseases Research Institute, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia., Kirschner MB; Asbestos Diseases Research Institute, Sydney, Australia.; Current address: Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland., Sarun KH; Asbestos Diseases Research Institute, Sydney, Australia., Schelch K; Asbestos Diseases Research Institute, Sydney, Australia.; Current address: Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria., Winata P; Asbestos Diseases Research Institute, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia., McCaughan B; PAH Medical Centre, Sydney, Australia., Kao S; Asbestos Diseases Research Institute, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Chris O'Brien Lifehouse, Sydney, Australia., Van Zandwijk N; Asbestos Diseases Research Institute, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Current address: Sydney Local Health District, Concord, Australia., Reid G; Asbestos Diseases Research Institute, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Current address: Department of Pathology, University of Otago, Dunedin, New Zealand.

Publikováno v: Oncotarget [Oncotarget] 2019 Jun 25; Vol. 10 (41), pp. 4125-4138. Date of Electronic Publication: 2019 Jun 25 (Print Publication: 2019).

BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

Autor: Rath EM; Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia., Cheng YY; Asbestos Diseases Research Institute (ADRI), Concord, NSW, Australia.; University of Sydney, Sydney, NSW, Australia., Pinese M; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Sydney, NSW, Australia., Sarun KH; Asbestos Diseases Research Institute (ADRI), Concord, NSW, Australia., Hudson AL; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, NSW, Australia., Weir C; Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, NSW, Australia., Wang YD; Burns Research, ANZAC Research Institute, Concord Hospital, University of Sydney, Concord, NSW, Australia., Håkansson AP; Division of Experimental Infection Medicine, Lund University, Lund, Sweden., Howell VM; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, NSW, Australia., Liu GJ; Australian Nuclear Science and Technology Organisation (ANSTO), New Illawarra Rd, Lucas Heights, NSW, Australia.; Brain and Mind Centre and Faculty of Health Sciences, University of Sydney, Sydney, NSW, Australia., Reid G; Asbestos Diseases Research Institute (ADRI), Concord, NSW, Australia.; University of Sydney, Sydney, NSW, Australia., Knott RB; Australian Nuclear Science and Technology Organisation (ANSTO), New Illawarra Rd, Lucas Heights, NSW, Australia., Duff AP; Australian Nuclear Science and Technology Organisation (ANSTO), New Illawarra Rd, Lucas Heights, NSW, Australia., Church WB; Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia.

Publikováno v: PloS one [PLoS One] 2018 Aug 29; Vol. 13 (8), pp. e0203003. Date of Electronic Publication: 2018 Aug 29 (Print Publication: 2018).

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

Autor: Kao SC; Asbestos Diseases Research Institute, Sydney, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia., Cheng YY; Asbestos Diseases Research Institute, Sydney, Australia., Williams M; Asbestos Diseases Research Institute, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia., Kirschner MB; Asbestos Diseases Research Institute, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia., Madore J; Sydney Medical School, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia., Lum T; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia., Sarun KH; Asbestos Diseases Research Institute, Sydney, Australia., Linton A; Asbestos Diseases Research Institute, Sydney, Australia; Department of Medical Oncology, Concord Cancer Centre, Sydney, Australia., McCaughan B; Sydney Medical School, The University of Sydney, Sydney, Australia; Sydney Cardiothoracic Surgeons, RPAH Medical Centre, Sydney, Australia., Klebe S; Department of Anatomical Pathology, Flinders University and SA Pathology at Flinders Medical Centre, Adelaide Australia., van Zandwijk N; Asbestos Diseases Research Institute, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia., Scolyer RA; Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia; Department of Medical Oncology, Concord Cancer Centre, Sydney, Australia., Boyer MJ; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia., Cooper WA; Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia; School of Medicine, Western Sydney University, Sydney, Australia., Reid G; Asbestos Diseases Research Institute, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia. Electronic address: glen.reid@sydney.edu.au.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2017 Sep; Vol. 12 (9), pp. 1421-1433. Date of Electronic Publication: 2017 Jun 16.